Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AstraZeneca's Tagrisso Approved in China Following Priority Review

publication date: Mar 28, 2017
AstraZeneca has been granted CFDA approval for Tagrisso, the company's third-generation EGFR inhibitor, as a treatment for non-small cell lung cancer. The oral drug was approved as a second-line treatment for EGFR T790M mutation-positive NSCLC. According to AstraZeneca, patients who are given earlier EGFR inhibitors (such as Roche's Avastin and its own Iressa) often develop the T790M mutation over time, causing resistance and providing AstraZeneca with a market for Tagrisso. The China approval was granted under CFDA priority review rules, a first for AstraZeneca in China. More details....

Stock Symbols: (NYSE: AZN) (SIX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital